Drug
Buparlisib clinical trials
Also written BKM120.
- studies test it
- 81
- open now
- 0
- in phase 3
- 3
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
81 studies that test it; most in 2012 (23)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 14 |
| 2012 | 23 |
| 2013 | 13 |
| 2014 | 19 |
| 2015 | 6 |
| 2016 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 45
- Phase 2
- 37
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 47
Novartis Pharmaceuticals (30) · Dana-Farber Cancer Institute (4) · Memorial Sloan Kettering Cancer Center (4) · SCRI Development Innovations, LLC (3) · Canadian Cancer Trials Group (2) · Roswell Park Cancer Institute (2) · Washington University School of Medicine (2) · Adlai Nortye Biopharma Co., Ltd. (1)
Often tested with
Tested in the same studies.
Alpelisib (4) · Paclitaxel (4) · Cisplatin (3) · Dactolisib (3) · Carboplatin (3) · Binimetinib (2) · Ribociclib (2) · Sonidegib (2)
Studies
Open first, then newest update. How each study uses buparlisib is read from its arms, and is right about nine times in ten.
Testing it · 81
- Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast CancerTerminatedPhase 1/2Institut Paoli-CalmettesNCT01589861Written as BKM120 + lapatinib
- Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid TumorsCompletedPhase 1Adlai Nortye Biopharma Co., Ltd.NCT04975958Written as AN2025
- Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and NeckCompletedPhase 1Dana-Farber Cancer InstituteNCT02113878Written as BKM120
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedPhase 2PfizerNCT02159066Written as BKM120
- GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial CancerCompletedPhase 2ARCAGY/ GINECO GROUPNCT01397877Written as BKM120
- Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic LeukemiaCompletedPhase 2Canadian Cancer Trials GroupNCT02340780Written as Buparlisib
- P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.CompletedPhase 1/2Canadian Cancer Trials GroupNCT01591421Written as BKM120
- Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid TumorsWithdrawnPhase 1Roswell Park Cancer InstituteNCT01971489Written as Buparlisib
- A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFRCompletedPhase 1National Cancer Centre, SingaporeNCT01570296Written as Gefitinib and BKM120
- A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02756247Written as Buparlisib
- Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian CancerWithdrawnPhase 1Rutgers, The State University of New JerseyNCT02117817Written as BKM120
- PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or MetastaticCompletedPhase 1Roswell Park Cancer InstituteNCT01540253Written as PI3K inhibitor BKM120
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedPhase 1Kami Maddocks, MDNCT02049541Written as PI3K inhibitor BKM120
- A Study of BKM120 (Buparlisib) in Relapsed or Refractory ThymomasCompletedPhase 2Patrick Joseph Loehrer Sr.NCT02220855Written as BKM120
- STAR Cape+BKM120 MBC With Brain MetCompletedPhase 2US Oncology ResearchNCT02000882Written as BKM120
- BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line ChemotherapyTerminatedPhase 2Prince of Songkla UniversityNCT01806649Written as BKM120
- PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedPhase 1/2University of ChicagoNCT01816984Written as PI3K inhibitor BKM120
- Buparlisib in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT01551030Written as Buparlisib
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedPhase 1Dana-Farber Cancer InstituteNCT01623349Written as BKM120 and Olaparib
- Neoadjuvant BKM120 in High-risk Prostate CancerTerminatedPhase 2Won KimNCT01695473Written as BKM120
See all 81 studies that test buparlisib →
Given in every arm · 3 — buparlisib is usual care beside what is tested
- Phase II Study of BKM120 for Subjects With Recurrent GlioblastomaCompletedPhase 2L. Nicolas Gonzalez Castro, MD, PhDNCT01339052Written as BKM120
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedPhase 1Emory UniversityNCT02614508Written as Buparlisib
- Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerTerminatedPhase 1/2Novartis PharmaceuticalsNCT01132664Written as BKM120
As the comparator · 1 — what is tested is compared with buparlisib
Codes
What other systems call buparlisib · ClinicalTrials.gg INT006021
- UNII (FDA) 0ZM2Z182GDBUPARLISIBConfirmed FDA, Wikidata
- Wikidata Q25100534buparlisibConfirmed FDA, Wikidata
- NCI Thesaurus C90565BuparlisibOne source FDA
- DrugBank DB11666One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0ZM2Z182GD | BUPARLISIB | Confirmed FDA, Wikidata |
| Wikidata | Q25100534 | buparlisib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C90565 | Buparlisib | One source FDA |
| DrugBank | DB11666 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.